Yesterday, Schering-Plough Corp. (SGP) said it has signed an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma Inc., which sought to make generic versions of its allergy drug Clarinex.

This signals the end of all pending litigations that Schering filed against several generic drug manufacturing companies in the US District Court of New Jersey since 2006. These companies wanted to market solid oral doses of the drug, desloratadine, in the U.S. as generic brands before the expiration of certain Schering patents.

Pursuant to the agreement, Orchid received rights to launch a generic version of the Clarinex brand Reditabs in the U.S. on Jan. 1, 2012 and Clarinex brand 5 milligram tablets on July 1 of that year. Schering holds various patents related to Clarinex till 2022.

Schering has previously resolved similar disputes with Caraco Pharmaceutical Laboratories Ltd. (CPD), Dr. Reddy’s Laboratories Inc. (RDY), GeoPharma Inc. (GORX), Mylan Pharmaceuticals Inc. (MYL), Perrigo Co. (PRGO) and Watson Pharmaceuticals Inc. (WPI), among others.

Clarinex brands provide relief from seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria or hives of unknown cause.

Schering is currently gearing up for its proposed $41.1 billion merger with Merck & Co Inc. (MRK). The deal, which will bring many top-selling products under one umbrella, is expected to close in the fourth quarter. The combined entity will have a more diverse portfolio across important therapeutic areas like cardiovascular, respiratory, oncology, neuroscience, infectious disease, immunology and women’s health. We await more visibility into the merger before recommending Schering’s shares to investors.

Zacks Investment Research
View original at: Zacks.com News Feed

1. (PFE) Pharmaceuticals & Biotech – Zacks Analyst InterviewsThe pharmaceutical industry is entering a period of substantial change in 2009. Most of the...
2. (PFE) Pharmaceuticals & Biotech – Industry OutlookThe pharmaceutical industry is entering a period of substantial change in 2009. Most of the...
3. (PRX) Par Pharmaceutical Companies, Inc. – Value – Zacks Rank BuyPar Pharmaceutical Companies, Inc. (PRX), the generic drug manufacturer, saw revenue grow 32% as sales...
4. (MRK) Drug Companies: A Powerhouse of Profitsby The Investment U Research Team A couple of interesting news items came out in...
5. (WPI) Watson Pharmaceuticals, Inc. – Value – Zacks Rank BuyWatson Pharmaceutical Inc. (WPI), a generic and branded drug manufacturer, has surprised on earnings 3...
6. (WYE) Biotech Industry – Industry OutlookOVERVIEW The financial market and the economic landscape in the U.S. have not changed much...

Search Posts by Tag: Caraco Pharmaceutical Laborato | CPD | Dr. Reddys Laboratories | GeoPharma Inc. | GORX | Merck & Company Inc. | MRK | MYL | Mylan | Perrigo Company | PRGO | RDY | Schering-Plough Corp. | SGP | Watson Pharmaceuticals Inc. | WPI | Drug Manufacturers - Major | Healthcare

RSS Feeds by Tag: Caraco Pharmaceutical Laborato | CPD | Dr. Reddys Laboratories | GeoPharma Inc. | GORX | Merck & Company Inc. | MRK | MYL | Mylan | Perrigo Company | PRGO | RDY | Schering-Plough Corp. | SGP | Watson Pharmaceuticals Inc. | WPI | Drug Manufacturers - Major | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author